| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Anti-GPC3 chimeric antigen receptor T cell therapy (Hunan Zhaotai Yongren Biotech/Guangdong Zhaotai Invivo Biomedicine) | Phase 1 Clinical | Guangdong Zhaotai Invivo Biomedicine Co Ltd, Hunan Zhaotai Yongren Biotech Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |